NCT05788497View on ClinicalTrials.gov

Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemorrhoids

PHASE3TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 30, 2023

Primary Completion Date

January 4, 2024

Study Completion Date

January 4, 2024

Conditions
Haemorrhoids Without Complication
Interventions
DRUG

Hemorrane plus

Hemorrane 10 mg/g rectal ointment + 30 mg/g benzocaine

DRUG

Hemorrane

Hemorrane 10 mg/g rectal ointment

DRUG

Placebo

Rectal ointment

Trial Locations (13)

5001

CS Ávila Estación, Ávila

28006

CS Montesa, Madrid

28009

CS Goya, Madrid

28034

CS Fuencarral, Madrid

28044

CS General Fanjul, Madrid

28850

CS Las Fronteras, Torrejón de Ardoz

28914

CS Dr. Mendiguchia Carriche, Leganés

36680

CS A Estrada, A Estrada

46010

CS Trinitat, Valencia

46023

CS Trafalgar, Valencia

08860

CAP Can Bou, Castelldefels

08757

CAP Corbera de Llobregat, Corbera de Llobregat

08028

CAPSBE Les Corts, L'Hospitalet de Llobregat

Sponsors

Lead Sponsor

Faes Farma, S.A.
All Listed Sponsors
collaborator

Dynamic Science S.L.

INDUSTRY

lead

Faes Farma, S.A.

INDUSTRY

NCT05788497 - Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemorrhoids | Biotech Hunter | Biotech Hunter